MS Quiz Flashcards
Name at least 3 medications that are FDA approved for MS that can be administered orally.
Fingolimod, dimethyl fumarate, teriflunomide (these are the 3 first line PO drugs for MS)
This medication is a humanized monoclonal antibody directed against integrin. It is administered IV once a month. JC antibody status should be assessed at 6 month intervals in all patients receiving treatment. Alternative therapy is recommended for antibody positive patients.
A) Interferon beta
B) Dimethyl fumarate
C) Natalizumab
D) Alemtuzumab
C
This medication binds to MHC molecules, displacing bound myelin basic protein (MBP). It is administered SC either daily or 3 times a week. Administration related reactions are similar to interferon.
A) Alemtuzumab
B) Terifunomide
C) Dimethyl fumarate
D) Glatiramer
D
This medication has the strongest evidence for efficacy and longterm safety with respect to MS.
Interferon beta
Which of the following drugs has been shown to reduce the duration of significant MS relapses?
A) Metoprolol
B) Amantadine
C) IV methylprednisolone
D) Metoprolol XL
C – IV methylprednisolone (1000 mg daily for 3-5 days) is given to reduce the duration of significant MS relapses. But. it does not alter the frequency or risk for future relapses or disease progression
Which of the following is recommended in regard to disease modifying therapy (DMT)?
A) Clinicians should counsel patients with relapsing MS that teriflunomide use is safe during pregnancy and conception
B) Clinicians should counsel patients with relapsing MS who are considering d/c natalizumab that doing so is associated with an increased risk for relapse or MRI detected disease within 6 months
C) Clinicians should counsel patients with relapsing MS that DMTs are intended only for symptom improvement
B
Which of the following is accurate regarding immunomodulatory therapy for relapsing-remitting MS (RRMS)?
A) Alemtuzumab is reserved for patients with RRMS who have an inadequate response to two or more other drugs for MS
B) Natalizumab is indicated as part of combination therapy in patients with RRMS as part of a first line DMT
C) Glatiramer acetate is approve by the US FDA to slow disability
D) Fingolimod is primarily indicated for patients with RRMS who have other preexisting conditions, such as recent myocardial infarction or unstable angina
A – alemtuxumab d/t its toxicity, is reserved for use in patients who have an inadequate response to two or more other drugs for MS
Glatiramer does improve relapse rates, but it is unclear if Glatiramer improves disease progression
Natalizumab is indicated as monotherapy for the treatment of patients with relapsing forms of MS to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. It is generally used in patients who have not responded to a first line DMT or who have very active disease
Fingolimod is CI in patients with recent MI, UA, etc.
